Morgan Stanley cuts Evercore Partners stock price target on revenue outlook

Morgan Stanley cut Evercore’s price target to $376 from $384 while keeping an Equalweight rating, after raising 2026 EPS to $21.72 and lowering 2027 EPS to $27.83. The new target still uses a 13.5x multiple on 2027 EPS, with higher compensation ratios partly offsetting lower tax and expense assumptions. Evercore also posted a strong Q1 2026 beat, with adjusted EPS of $7.53 versus $5.18 expected and revenue of $1.4 billion versus $1.16 billion expected.

Analysis

The key signal is not the headline target cut; it is the widening dispersion inside the earnings model. Lower revenue assumptions alongside higher comp ratios tell you the street is still underestimating how quickly operating leverage can reverse in a weaker fee environment, especially for a business where a small change in deal activity can swing margins materially. That makes this less about a clean downgrade and more about a narrowing path to upside: if advisory rebounds, the equity can rerate fast; if it doesn’t, earnings estimates can keep drifting lower despite apparently cheap valuation optics.

For Evercore, the market is likely pricing the recent beat as evidence of cyclical inflection, but the analyst revisions imply that peak margins may be closer than the print suggests. The second-order issue is competitive: the strongest independent advisory franchises can steal share when mid-market and sponsor clients prioritize senior attention, but that benefit is fragile if broader underwriting and ECM volumes stay soft. In that case, hiring and compensation discipline become the real battleground, and names with better fixed-cost control should outperform on any revenue disappointment.

The more interesting setup is time horizon mismatch. Near term, a strong quarter can keep the stock supported for days to weeks, but over 3-6 months the stock will trade on whether transaction backlog converts into actual closings and whether buyback/dividend capacity remains intact after comp normalization. If the cycle rolls over, the current multiple support can compress quickly because the market tends to punish advisory firms for estimate cuts more than it rewards one-quarter beats.

Consensus may be underweighting how much of the valuation case depends on maintaining elevated earnings power rather than just a low PEG. A low PEG is only helpful if the denominator is durable; here, the denominator is exposed to fee cyclicality and compensation leverage. That creates a setup where the stock can look statistically cheap while still being vulnerable to another round of estimate reductions if capital markets activity does not broaden beyond a few pockets of strength.

Key Decisions for Investors

• Stay tactically long EVR only into weakness, but use a 1-2 month horizon and treat it as a trading position, not a core hold; upside is driven by continued estimate revisions, while downside accelerates if deal conversion softens.
• Buy EVR Jan/Feb put spreads if the stock rallies back toward the revised target area; the risk/reward favors limited-premium downside protection if the market starts discounting lower 2027 earnings again.
• Pair trade: long EVR / short a more levered fee-sensitive financials basket if you want to express quality in independent advisory; if M&A sentiment improves, EVR should capture disproportionate upside versus weaker franchises.
• If you are already long EVR, hedge with a short-dated call overwrite into earnings windows; the stock’s near-term reaction is likely to be event-driven, while the model risk is slow estimate erosion over the next 2-3 quarters.
• Watch for confirmation in advisory backlog and compensation ratio trends over the next two reporting cycles; if comp stays above expectations without a matching revenue inflection, reduce exposure aggressively.